Spots Global Cancer Trial Database for Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
Official Title: Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
Study ID: NCT02949570
Conditions
Interventions
Study Description
Brief Summary: To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
Detailed Description: To determine: * Duration of response * Progression free survival * Proportion of responders 2 years after discontinuation of inecalcitol * Duration of response after discontinuation of inecalcitol and imatinib * Bone remodelling effect * Safety of inecalcitol in combination with imatinib * Quality of Life
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHU Côte de Nacre, Caen, , France
Contact Details
Name: Jean-Francois Dufour-Lamartinie, MD
Affiliation: Hybrigenics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
